Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Abstract
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1–based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1–based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerns regarding pancreatitis have not been substantiated in large cardiovascular outcome trials (92, 93).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [92]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [8], but they generally diminish over time, with their occurrence being dose-dependent.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [8]
In the citing paper
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70-85% of patients and lead to treatment discontinuation [22,38,41,60,61]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [41]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Self-citationEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403347 · Cited by 2,099
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Research works printed but not linked: 1
- Styrkarsdottir, Obesity variants in the GIPR gene do not associate with risk of fracture or bone mineral density, J Clin Endocrinol Metab
Cited by
Items 201–300 of 381
Adnan, S., Qureshi, M., Arif, S., & Fatima, K. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70336 · Cited by 1
“According to Drucker, 9 psychiatric symptoms, such as agitation and eating disorders, have been correlated with GLP 1RAs use.”
Eliminating viscosity challenges in continuous cultivation of yeast producing a GLP-1 like peptide
Voulgaris, I., Nielsen, A. N., Petersen, T., & Jensen, S. (2025) · Microbial Cell Factories · doi:10.1186/s12934-025-02745-6 · Cited by 2
“GLP-1RAs, including semaglutide, tirzepatide, and liraglutide, have gathered considerable attention due to their favorable pharmacological properties, such as enhanced glucose-dependent insulin secretion, weight reduction and cardiovascular benefits [1].”
Li, H., Ma, Q., Xu, L., Zheng, C., Lin, L., Gu, J. L., Huang, X., Yang, H., Xu, H., Xu, F., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00194 · Cited by 1
Glucagon-Like Peptide-1-Receptor Agonist Treatment of Obesity: Is It Cost-Effective and Equitable?
Hertzer, L., & Siegel, R. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114779 · Cited by 1
Seika, P., Chang, J. J., Hong, S. M., Ballou, S., Rangan, V., Ramprasad, C., Iturrino, J., Denecke, C., Lembo, A. J., Nee, J. W., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.08.015 · Cited by 1
Singhal, R., Sachdeva, D., Wortman, K., II, & Lall, R. (2025) · Cureus · doi:10.7759/cureus.91679 · Cited by 13
“…(subcutaneous, once weekly) and Rybelsus (oral, once daily) for type 2 diabetes mellitus, and as Wegovy (subcutaneous, once weekly) for obesity irrespective of diabetes status, have become a cornerstone therapy owing to their efficacy in improving glycemic control and promoting weight loss [5].”
Cheng, J., Yu, H., Gu, Y., Ma, C., Li, C., Pan, Z., & Yuan, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70152 · Cited by 3
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2
GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1
Sun, R., Wang, Y., Shu, H., Li, L., Yao, J., Su, X., Shi, B., Wu, C., Ma, J., & WANG, Q. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70262 · Cited by 1
“Eligible participants were 18 – 75 years old, diagnosed with T2D per WHO 2020 criteria, with HbA1c 7.0 – 11.0%, fasting plasma glucose (FPG) 13.9 mmol/L, BMI 24 – 40 kg/m 2 , and no glucose-lowering medications within 8 weeks before screening.”
InfluentialSpecial Issue “Diabetes: Comorbidities, Therapeutics and Insights (2nd Edition)”
Bulum, T. (2025) · Biomedicines · doi:10.3390/biomedicines13123037 · Cited by 1
“These medications have revolutionized the treatment of type 2 diabetes and obesity, but their impact on vestibular function remains unclear [33].”
Liu, T., Hsu, C.-H., Wu, J., Huang, P., Chang, C., & Lai, C.-C. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.016 · Cited by 5
Dang, D. X., Xu, S. Q., Li, D., Xia, X., & Xu, S. (2025) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2025.102548 · Cited by 1
Nauman, E., McTigue, K. M., Shenkman, E. A., Djibo, D. A., & Carton, T. W. (2026) · Medical Care · doi:10.1097/mlr.0000000000002244 · Cited by 2
“12 OneFlorida+ has a data use agreement with the Agency for Healthcare Administration that oversees the Florida Medicaid Program.”
Shah, P. P., & Bhattacharya, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101418 · Cited by 2
“Since the first GLP-1RA (exenatide) was approved in 2005, this class of medications has amassed extensive clinical trials and real-world usage, establishing a robust safety and efficacy record [3 – 5].”
Zhang, H., Li, S., Kan, J., Xia, T., Cao, N., & Chen, H. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05511-7 · Cited by 2
“GLP-1 RAs suppress appetite, reduce visceral fat, and improve insulin sensitivity, directly targeting METS-VF’s core components [52].”
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials
McManus, K. R., & Ray, L. A. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2625341 · Cited by 2
“(NCT05520775), a GLP-1RA, in non-treatment seeking individuals with AUD revealed that low-dose semaglutide (i.e. 0.”
Poole, E. M., Al-Issa, M., Dong, J., Shelp, G. V., Burns, S. E., Monk, J. M., Dyck, D. J., & Cho, C. E. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101389 · Cited by 2
“Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted by enteroendocrine L-cells predominantly found in the distal colon, has emerged as a potential therapeutic target for type 2 diabetes [18,19].”
GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap?
Beji, S., & Caron, A. (2026) · Neuroendocrinology · doi:10.1159/000550812 · Cited by 1
“Importantly, the superior weight-loss efficacy of GLP-1R/GCGR co-agonists and tri-agonists does not currently translate into demonstrated preservation of lean mass in humans [19, 69].”
Long, Z., Li, J., Zhu, F., Liu, X., Zhou, J., Li, J., & Xu, W. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151199 · Cited by 1
An engineered micropatch for oral delivery of heterophyllin B in type 2 diabetes treatment
Chen, Y., Huang, Y., Huang, C., Zhang, S., Fan, M., Yuan, X., Huang, C., Zhang, M., Peng, J., 孙润彬, et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114782 · Cited by 1
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
“These occur due to a combination of slowed gastric emptying and activation of central nervous aversive responses [78].”
Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide – a review
Lu, M. (2026) · International Journal of Retina and Vitreous · doi:10.1186/s40942-026-00811-8 · Cited by 2
“Glucagon-like peptide-1 (GLP-1)-based therapies have transformed the management of type 2 diabetes (T2D) and obesity, demonstrating exceptional efficacy in glycemic control and weight reduction [1].”
InfluentialZhang, W., Xue, J., Wang, J., Ni, D., Zhou, W., Wang, B., Shi, J., & Wang, A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.210 · Cited by 2
Ge, Y., Tang, Y. F., Lu, Y., Hou, S., Dai, Z., Xiong, R., Chen, S., Li, Y., & Xia, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1783967 · Cited by 1
The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
Jafari, S. M. S., Caro, G., Lipner, S. R., & Iorizzo, M. (2026) · American Journal of Clinical Dermatology · doi:10.1007/s40257-026-01021-6 · Cited by 6
“…approved for the treatment of type 2 diabetes mellitus, their clinical use has expanded to include obesity management in patients with a body mass index (BMI) ≥ 30 kg/m 2 , or ≥ 27 kg/m 2 in the presence of comorbidities like arterial hypertension (HTN), prediabetes/diabetes, or dyslipidemia [2–5].”
Kreidieh, D., Ballout, R., Abutaima, R., Kharroubi, S. A., & Saleh, F. A. (2026) · BMC Public Health · doi:10.1186/s12889-026-27162-1 · Cited by 1
“The most frequently reported side effects are gastrointestinal, described as mostly mild-to-moderate [13].”
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Ahmed, E. O., Gasmallah, S. I., Jalal, M., Ahmed, W. R., & Fadul, K. H. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261441498 · Cited by 2
“29,30 The slowing of gastric emptying associated with GLP-1RAs raises concerns about intestinal obstruction and perioperative aspiration, and regulatory agencies have issued warnings regarding serious GI complications and potential risks such as pancreatitis and thyroid safety concerns.”
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Saeed, Z. I., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.006 · Cited by 1
Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease
Wu, J.-Y., Lin, Y.-M., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., & Lai, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838392 · Cited by 1
Anatriello, A., Liguori, V., Pentella, C., Zinzi, A., Longo, M., Caruso, P., Maiorino, M. I., Esposito, K., & Capuano, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00864-4 · Cited by 1
Min, E., Goyette, A., Young, E., Moon, K., Bellini, N. J., & Isaacs, D. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0142 · Cited by 1
Hyung, B., Ye, X. Y., Chandrakumar, M., Lovshin, J. A., & Peacock, S. C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70955 · Cited by 2
“GLP-1RAs modify gastric motility and delay gastric emptying via dose-dependent GLP-1RA signalling by central and peripheral mechanisms [5].”
Castrellon, R., Maita, K., Witt, E., Young, V., Torres-Guzman, R. A., & Huaman, G. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-05953-6 · Cited by 1
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, have significantly advanced the treatment of obesity and type 2 diabetes through their potent effects on appetite regulation and metabolic control [1–3].”
Song, K., Zhang, Q., Li, S., Du, Q., Ng, S. K., Chen, Y., Pu, Y., Widjaja, J., Chen, H., & Chen, Y. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00726-3 · Cited by 1
“These genetic conditions are explicitly listed as contraindications in the prescribing information for GLP-1 receptor agonists due to findings of C-cell tumor development in rodent studies, although the human relevance remains uncertain [25].”
Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Shahd, A., Bridges, N., & Goldstone, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1881392 · Cited by 1
Fu, X., Xie, Y., Xie, Y., Han, A., Zhou, X., Zhang, S., Shen, C., Zhang, Y., Wang, L., & Xie, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1860661 · Cited by 1
Huang, Y., Liu, K.-W., Li, P., Chen, J.-C., Meyerowitz‐Katz, G., Su, P., & Huang, C. (2026) · Communications Medicine · doi:10.1038/s43856-026-01750-z · Cited by 3
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
Krishna, S., Dungan, K. M., Shah, R., Cruz‐Monserrate, Z., DelGiorno, K. E., Tan, M., & Hart, P. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00069-9 · Cited by 1
Yang, Z., Li, X., Wu, N., Wang, L., Lu, Z., Wang, L., Han, S., & Lu, H. (2026) · Stem Cell Reports · doi:10.1016/j.stemcr.2026.103008 · Cited by 1
“…agonists (GLP-1RAs), such as semaglutide, have attracted considerable attention for metabolic benefits in type 2 diabetes, obesity, and cardiovascular events (Drucker, 2024; Ussher and Drucker, 2023); however, their effects on the skeletal sys-tem remain generally neutral but controversial.”
Valizada, H., & Zilbermint, M. F. (2026) · Cureus · doi:10.7759/cureus.113026 · Cited by 1
“The GLP-1 receptor agonists have become widely used in the treatment of obesity and diabetes mellitus because of their proven efficacy and additional metabolic benefits [11].”
Li, X., Liu, Y., Wang, F., Zhang, F., Zhang, L., Dang, Y., & Qi, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07958-4 · Cited by 1
Jiang, J., Shi, M., Wu, S., & Cao, M. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00287 · Cited by 4
Feldman-Billard, S. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.4521 · Cited by 1
Betagenin ameliorates diabetes by inducing insulin secretion and β-cell proliferation
Yokoo, T., Watanabe, K., Iida, K., Nakachi, Y., Suzuki, H., Shimano, H., Takashima, S., Okazaki, Y., Yamada, N., & Toyoshima, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108202 · Cited by 3
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Thomas, T. S., & Srinivasa, S. (2024) · PubMed Central · Cited by 7
Britt, M., Abdilmasih, N., & Rezanejad, H. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-10859-y · Cited by 2
McIntyre, R. S., Zhang‐James, Y., Goldberg, J. F., & Kwan, A. T. H. (2026) · medRxiv · doi:10.64898/2026.02.09.26345925 · Cited by 1
Anatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
“…in the presence of at least one weight-related comorbid condition (Ruggiero et al., 2024; Cimmaruta et al., 2016; Liu, 2024; Mariam and Niazi, 2024; European Medicines Agency EMA, 2025a; European Medicines Agency EMa, 2025b; European Medicines Agency EMA, 2025c; Drucker, 2024; Trujillo, 2020).”
GLP-1-receptoragonisten en renoprotectie in type 2-diabetes
Muskiet, M. H. A., & Apperloo, E. M. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1567-6
SAFETY OF GLP-1RA THERAPY: SIDE EFFECTS AND THE NEED FOR MONITORING
Piasta, M., Mandryk, M., Grzesiak, M., & Szymański, O. (2024) · Health Problems of Civilization · doi:10.5114/hpc.2024.142668
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes Care · doi:10.2337/dci24-0092 · Cited by 3
Browning, T. E., Coy, A., Sehgal, V., Singh, S., Jakhar, N. S., Sehgal, P., & Kukreja, M. (2025) · doi:10.25259/peak_19_2024 · Cited by 1
Medikamentöse Therapie der Adipositas bei Kindern und Jugendlichen
Lischka, J., Torbahn, G., Mörwald, K., Gomahr, J., Jabbour, J., Geiersberger, S., & Weghuber, D. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02149-1 · Cited by 1
Cattaneo, D., Ridolfo, A. L., Giacomelli, A., Cossu, M. V., Dolci, A., Gori, A., Antinori, S., & Gervasoni, C. (2025) · Diabetology · doi:10.3390/diabetology6030020
“The treatment of type 2 DM has been revolutionized by the discovery of glucagon-like peptide 1 receptor agonists (GLP1-RAs) [10].”
Zhang, Z., Liu, S., Xian, J., Zhang, Y., Zhang, C., Wang, Z., Deng, H., Feng, J., & Yao, L. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26154
“Furthermore, the potential impact of liraglutide on weight control [104,105] may significantly contribute to the observed improvement in cardiovascular mortality.”
How Increasing Adiposity Impacts Communicable Disease Risk at a Global and a Cellular Level
Woodcock, A., & Cassidy, F. C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009202
Glucagon-like-peptide 1 (GLP-1) Receptor Agonists in Rheumatologic Disease
Trinacty, J., & Rostom, K. (2025) · Canadian rheumatology today. · doi:10.58931/crt.2025.2158
Les analogues de GLP-1 dans l’arthrose : avancées et perspectives
Berenbaum, F. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.06.003
Chen, C., & Chen, S. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70058
Efectividad de los agonistas del receptor GLP-1 en el manejo de pacientes diabéticos tipo 2
Bejarano‐Romero, F., Molés, V. A., Porrúa, D. M., Guerrero, E. L., Barriga, H. S., & Vilarrasa, L. C. (2025) · Atención Primaria · doi:10.1016/j.aprim.2025.103354 · Cited by 1
The need for improved diabetes detection and treatment
Sørensen, H. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00250-5
Hu, J., Zhou, Y., Liu, S., Li, J., Tian, L., & Liang, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00044-5
Triozzi, J. L., Chen, H., Mamak, F., Yu, Z., Wilson, O. D., Ikizler, T. A., Ferolito, B. R., Cho, K., Gaziano, J. M., Tao, R., et al. (2025) · medRxiv · doi:10.1101/2025.10.13.25337903
“However, long-term clinical data are limited [5].”
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Pawar, M., Patil, C. S., Fakir, J. S., Pagar, D. S., & Mahajan, S. K. (2025) · BioMed Target Journal · doi:10.59786/bmtj.322 · Cited by 1
Glucagon-Like Peptide 1-Based Therapies: Panacea or Cautionary Tale?
Ponte, C. D., Rosselli, J. L., Isaacs, D. M., Cantazaro, M., & Naseman, K. (2025) · ADCES in Practice · doi:10.1177/2633559x251390515
López, G. P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107122 · Cited by 2
Ramsbacher, N., & Neumiller, J. J. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408486-references
Mover, K., Crowsey, E., Hux, V., Jones, T., Lababidi, S. L., & Peplinski, B. (2025) · Women s Health Reports · doi:10.1177/26884844251401523
Wei, N., Yuan, S., Gao, L., Zhang, B., Yan, Z., Gao, C., Meng, Y., & Cui, Y. (2025) · Antioxidants · doi:10.3390/antiox15010021
“Some peptide drugs have been proposed to treat senescence-associated diseases in clinical practice, such as GLP-1 class drugs and SS-31 [37,38].”
Evaluating the Ocular Safety Profile of Glucagon-Like Peptide-1 Receptor AgonistsPreprint
Khan, Z., Chaudhry, F. W., Dhar, N., & Adyanthaya, R. S. (2025) · Research Square · doi:10.21203/rs.3.rs-8371495/v1
Júnior, W. E., dos Santos, R. G. M., Melo, W. A. S., da Costa, F. Z., Subar, G. G., Pavão, I. R., da Silva, J. R., de Souza, N. L. N., Cançado, M. A. F., Oliveira, C. H. G., et al. (2025) · Aracê. · doi:10.56238/arev7n12-333
A sex-specific brake on liver oestrogen signalling
Kakimoto, P. A., & Krahmer, N. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01427-2
Research progress in precision medicine for type 2 diabetes based on the GLP-1
Wang, S., Yuan, C., Wang, H., Ye, X., Ruan, S., Yi, L., Yang, W., Wang, Z., Wang, N., Li, J., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1721842 · Cited by 2
Khunte, M., Chetty, A. K., Ross, J. S., & Chen, A. S. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.10.021
Tks4 ‐Targeted Gene Therapy Inhibited White Adipocyte Hypertrophy in Mice
Tian, M., Deng, J., Hong, Y., Liu, R., Li, S., & He, X. (2026) · The FASEB Journal · doi:10.1096/fj.202503709rr
“Conversely, weight loss mediated by the Glucagon-like peptide 1 (GLP-1) receptor agonists is primarily driven by enhanced satiety and reduced hunger, leading to improved appetite control and decreased energy intake [5–7].”
Beas-Magdaleno, G. A., Schmidt-Ramrez, A., Muhlia-Prez, J. E., & Beas-Magdaleno, D. (2026) · Revista Mexicana de Anestesiología · doi:10.35366/122382 · Cited by 1
Stump, K., Morar, H., Talsania, A. J., Centeno, D., & Wiekrykas, B. D. (2026) · Hand · doi:10.1177/15589447261415646
Characterization of jejunal enteroids in human obesity; a model for studying GLP-1 cells
Osinski, C., Martínez-Oca, P., Moret, D., Genser, L., Poitou, C., Soula, H. A., Clément, K., Serradas, P., & Ribeiro, A. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02024-3 · Cited by 1
Huang, C., Lai, E. C., Wu, V., Hsieh, M. H., Li, C.-J., Chang, R., Chen, J.-S., Tsai, Y.-S., & Sung, J. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag028
Han, J., Kwon, O., Lee, Y. J., Choi, M., Lee, B., Kim, D., Noh, S., Cho, M., & Lee, Y.-M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041747
“However, their clinical application is frequently constrained by prohibitive costs and adverse gastrointestinal effects [20].”
Zou, Y., Cao, Z., Chen, Y., Yuan, M., Zhang, Z., Gu, W., Wang, J., Zhao, S., & Hong, J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s573217 · Cited by 1
“Considerable weight loss can be achieved through diverse approaches such as lifestyle modifications, 10,11 pharmaceutical interventions, 12,13 or bariatric surgical procedure.”
Lange, M. G., Vickers, A., Hill, L. J., Mollan, S. P., Mitchell, J., Sinclair, A. J., & Lee, A. G. (2026) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002431
Monnier, L., Schlienger, J.-L., & Colette, C. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.002
Diaz, M. E. C., Kim, G., & Vakharia, M. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156317
Shahriar, M. F., Kabir, J., & Kong, Y. (2026) · Molecular Diversity · doi:10.1007/s11030-025-11455-5
GLP-1 drugs may fight addiction across every major substance, according to a study of 600,000 people
Al-Aly, Z. (2026) · The Conversation · doi:10.64628/aai.h3med45fx
El Ozempic y otros fármacos GLP-1 podrían combatir la adicción a todo tipo de sustancias
Al-Aly, Z. (2026) · The Conversation · doi:10.64628/aao.q3hx74fs9
Ozempic e outros medicamentos GLP-1 podem ajudar a combater vícios em diversas substâncias
Al-Aly, Z. (2026) · The Conversation · doi:10.64628/ade.cnkywguyg
State of the art overview wearable glucose sensors based on nanosheets
Li, K., Liu, C., Li, Q., Tian, Z., Shi, H., Li, H., & Zhang, S. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100751
ElSayed, N. A., Okeke, O., Wiggins, T., Ebekozien, O. A., Segal, A. R., AbdElMoneim, J., Ibrahim, E., Hassanein, A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci26-0002
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Puga, T. B., Dieu, V. M., Haechten, T., O'Connor, K. P., Box, M. W., & Riehl, J. T. (2026) · Seminars in Arthroplasty JSES · doi:10.1016/j.sart.2026.151583
Nueva era terapéutica en la obesidad infantojuvenil: oportunidades y retos de futuro
Molina-Giraldo, P., Suárez-Ortega, L., & Ramon‐Krauel, M. (2026) · Anales de Pediatría · doi:10.1016/j.anpedi.2026.504194
A Deep Learning Prognostic Model for Diabetes Patients Using Bilateral Fundus Imaging
Lai, Y.-M., Chung, I.-F., Huang, S.-H., Sheu, W. H., Liang, K.-H., & Chen, H.-S. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261434035
Membrane progesterone receptor signaling reverses hyperglycemia and insulin resistance in obese micePreprint
Nader, N., Zarif, L., Sherif, S., Al-Hamaq, J., Qahtani, D. A., Courjaret, R. J., Yu, F., Abunada, H. H., Vemulapalli, P. B., Choi, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.27.714733
Neglected GLP-1 receptors in the eyes and nose: possible correlation with regulation of appetite
Saturnino, A., & Pozzilli, P. (2026) · Endocrine · doi:10.1007/s12020-026-04581-z · Cited by 1
Zhang, D. S., RAJAN, A., Islam, S., Charytan, D. M., Jacobson, A., Wright, D. R., Weiss, J., & Divers, J. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.03.012 · Cited by 1
Holliday, M. W., & Navaneethan, S. D. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001072
Metadata
- Authors
- Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-06-06
- Volume
- 47
- Issue
- 11
- Pages
- 1873-1888
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4399395008
- Semantic Scholar
- 306e8b284bd34405b3e79c99c37f0dec0c95f1ed
- Cited by
- 383
- References
- 171
- Citations by year
- 2026: 176 · 2025: 168 · 2024: 39
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes for Health Research (154321)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, tirzepatide, retatrutide, survodutide, cardiorenal benefits, drug safety, fracture, bone mineral density, muscle strength, gastrointestinal motility, anesthesia, pancreatic diseases, biliary tract diseases, cancer risk, cardiometabolic disease, personalized medicine
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.